Rotate to portrait

Vizual Stocks works best vertically on mobile.

VizualStocks API
PUBLIC DATA DEFINITIONS

Absci KPI & segment coverage

Operating KPI and segment definitions available for Absci (ABSI) through the VizualStocks API.

ABSI4 metric seriesCatalog checked 2026-10-28
Metric catalog API reference Open in the interactive demo

Active metrics 2

SEGMENT

Partner Program Revenue

Revenue recognized from Absci partner agreements for discovery, development, optimization and technology readiness using its Integrated Drug Creation platform. Historical observations use the technology-development revenue label; KBI joint-marketing collaboration revenue is excluded.

partnerProgramRevenue
Frequency
quarterly / annual
Reported history
Q1'21 — Q2'26
History endpoint
SEGMENT

Total Revenue

Total revenue recognized by Absci from partner drug-creation and technology-development agreements and its historical KBI joint-marketing collaboration. From 2023, this total equals the sole technology-development or partner-program revenue line.

totalRevenue
Frequency
quarterly / annual
Reported history
Q1'21 — Q2'26
History endpoint

Discontinued historical metrics 2

COMPANY KPI

Active Programs

Number of partnered drug-creation programs undergoing development to assess further advancement, plus programs whose partners maintain a license after the drug-creation phase, at period end. Terminated programs are removed; Absci announced it would stop reporting this KPI beginning with fiscal 2025.

activePrograms
Frequency
quarterly / annual
Reported history
Q1'21 — Q4'24
History endpoint
SEGMENT

Collaboration Revenue

Revenue recognized under Absci’s joint marketing agreement with KBI BioPharma to co-promote their technologies. The agreement ended in October 2022; this historical series excludes drug-creation and technology-development fees.

collaborationRevenue
Frequency
quarterly / annual
Reported history
Q1'21 — Q4'22
History endpoint